Calliditas Therapeutics (CALTX.ST) Stock Price
Calliditas Therapeutics Price
Over the last 8 years Calliditas Therapeutics grew revenue by 166.2% annually, reaching 1.21 B SEK. For Calliditas Therapeutics, the net margin of -38.6% is down versus -17.6% a few years ago.
Calliditas Therapeutics stock price
Details
Stock Price
ⓘHow to Read This Chart
This chart tracks the historical stock price of Calliditas Therapeutics over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.
Total Return vs. Price Return
The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.
Intraday Price Data
When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how Calliditas Therapeutics stock reacts to market openings, earnings releases, or breaking news throughout the trading session.
What to Look For
Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing Calliditas Therapeutics's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.
| Date | Calliditas Therapeutics Price |
|---|
Calliditas Therapeutics Revenue, EBIT, Net Income
3 Years
5 Years
10 Years
25 Years
Max
Details
Calliditas Therapeutics Income Statement, Balance Sheet, Cash Flow Statement
| REVENUEB SEK |
|---|
| REVENUE GROWTH% |
| GROSS MARGIN% |
| GROSS INCOMEB SEK |
| EBITB SEK |
| EBIT MARGIN% |
| NET INCOMEB SEK |
| NET INCOME GROWTH% |
| SHARESM |
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024e | 2025e | 2026e | 2027e | 2028e | 2029e |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | – | – | – | 0.18 | – | 0.23 | 0.80 | 1.21 | 1.87 | 3.77 | 5.22 | 6.92 | 8.62 | 4.70 |
| – | – | – | – | – | – | – | 250.22 | 50.37 | 54.98 | 101.55 | 38.60 | 32.48 | 24.56 | -45.46 |
| – | – | – | – | 100.00 | – | 100.00 | 98.13 | 93.62 | 93.62 | 93.62 | 93.62 | 93.62 | 93.62 | 93.62 |
| -0.05 | -0.06 | 1.13 | 1.13 | 0.18 | 1.13 | 0.23 | 0.79 | 1.13 | 1.75 | 3.53 | 4.89 | 6.48 | 8.07 | 4.40 |
| -0.05 | -0.06 | -0.08 | -0.13 | -0.03 | -0.38 | -0.52 | -0.42 | -0.38 | 0.18 | -2.26 | -3.14 | -4.16 | -5.18 | 2.32 |
| – | – | – | – | -15.22 | – | -228.82 | -52.49 | -31.84 | 9.58 | -60.10 | -60.12 | -60.11 | -60.12 | 49.46 |
| -0.05 | -0.06 | -0.09 | -0.13 | -0.03 | -0.44 | -0.51 | -0.41 | -0.47 | 0.08 | 1.22 | 2.19 | 3.41 | 4.69 | – |
| – | 9.80 | 53.57 | 53.49 | -75.76 | 1,262.50 | 16.74 | -19.06 | 13.11 | -116.09 | 1,528.00 | 79.36 | 55.80 | 37.49 | – |
| 53.67 | 53.67 | 66.46 | 70.40 | 77.42 | 49.94 | 52.34 | 53.26 | 53.67 | 53.67 | 53.67 | 53.67 | 53.67 | 53.67 | 53.67 |
Details
Income Statement Key Figures
ⓘRevenue and Revenue Growth
Revenue is the starting point of every income statement — it measures the total sales Calliditas Therapeutics generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.
Gross Margin
Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue Calliditas Therapeutics retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare Calliditas Therapeutics's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.
EBIT and EBIT Margin
EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.
Net Income and Earnings Per Share (EPS)
Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.
Shares Outstanding
The total number of shares Calliditas Therapeutics has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.
Analyst Estimates
The projected figures represent consensus estimates from professional analysts. Compare these forecasts against Calliditas Therapeutics's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.
Calliditas Therapeutics stock margins
3 Years
5 Years
10 Years
25 Years
Max
Details
Calliditas Therapeutics Stock Revenue, EBIT, Earnings per Share
3 Years
5 Years
10 Years
25 Years
Max
Details
Calliditas Therapeutics business model & stock analysis
Calliditas Therapeutics SWOT Analysis
Strengths
1. Strong Research and Development capabilities
2. Range of innovative and promising drug candidates in pipeline
3. Well-established collaborations and partnerships with key industry players
Weaknesses
1. Limited market presence and brand recognition compared to major competitors
2. Dependence on the success of clinical trials for drug candidates
3. Relatively small size and resources compared to industry leaders
Opportunities
1. Increasing demand for effective treatments in target therapeutic areas
2. Potential for strategic collaborations and licensing agreements
3. Expanding global pharmaceutical market
Threats
1. Intense competition from established pharmaceutical companies
2. Regulatory challenges and evolving market regulations
3. Potential risks associated with intellectual property rights
Calliditas Therapeutics Eulerpool Fair Value
Details
Fair Value Estimate
ⓘWhat Is Fair Value?
Fair value is an estimate of what a stock is truly "worth" based on its financial fundamentals, independent of the current market price. If the calculated fair value is above the current share price, the stock may be undervalued — and vice versa. This chart shows three different fair value approaches so you can cross-check them against each other.
Earnings-Based Fair Value
Calculated by multiplying the current earnings per share (EPS) by the average historical P/E ratio over a selected multi-year period. The smoothing over several years filters out temporary spikes or dips. If this fair value exceeds the market price, it suggests the stock is cheap relative to its earning power.
Example: Fair Value (Earnings) 2022 = EPS 2022 × Average P/E 2019–2021
Revenue-Based Fair Value
Derived by multiplying revenue per share by the average historical price-to-sales ratio. This method is particularly useful for companies with volatile or temporarily depressed earnings, as revenue tends to be more stable than profits. It answers: "At what price has the market historically valued each dollar of this company's sales?"
Example: Fair Value (Revenue) 2022 = Revenue per Share 2022 × Average P/S 2019–2021
Dividend-Based Fair Value
Calculated by dividing the dividend per share by the average historical dividend yield. This approach is most relevant for mature, consistently dividend-paying companies. If the resulting fair value is higher than the current price, it implies the stock offers a better yield than its historical average.
Example: Fair Value (Dividend) 2022 = Dividend per Share 2022 ÷ Average Yield 2019–2021
How to Use This Chart
When all three fair value lines converge above the current price, it strengthens the case that the stock is undervalued. When they diverge, investigate why — it may indicate a structural shift in margins, payout policy, or growth rate. The forward estimates on the right extend the analysis using projected fundamentals, helping you assess whether the current price already reflects future growth expectations.
Calliditas Therapeutics historical P/E ratio, EBIT multiple, and P/S ratio
Calliditas Therapeutics annual returns
Details
Annual Return
ⓘWhat This Chart Shows
This chart breaks down 's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.
Price Return
Price return measures the percentage change in 's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.
Dividend Return
Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.
What to Look For
Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare 's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.
Calliditas Therapeutics shares outstanding
3 Years
5 Years
10 Years
25 Years
Max
Details
Calliditas Therapeutics Analyst Rating Actions
| Date | Firm | Action | Rating | Reliability |
|---|---|---|---|---|
| 10/15/2023 | Maintained | Buy | – | |
| 8/20/2023 | Maintained | Buy | – | |
| 8/17/2023 | Maintained | Neutral | 30 | |
| 2/23/2023 | Maintained | Buy | 43 | |
| 12/19/2021 | Maintained | Buy | – |
Eulerpool Reliability Score (0–100): measures how often a firm’s bullish or bearish calls were directionally correct three months later, blended with the average return following its calls. Every rating we record is stored permanently and scores update continuously; firms with fewer than 3 measured calls are not scored yet.
Calliditas Therapeutics Earnings Estimates & Surprises
| Date | EPS estimate | EPS Actual | Revenue Estimate | Price reaction | Quarterly report |
|---|---|---|---|---|---|
| 5/14/2024 | 2.01SEK | - | 540.99 MSEK | - | 2024 Q1 |
| 2/21/2024 | -1.78SEK | - | 389.06 MSEK | - | 2023 Q4 |
| 8/16/2023 | 4.17SEK | - | 781.55 MSEK | - | 2023 Q2 |
| 5/16/2023 | 3.07SEK | - | 586.67 MSEK | - | 2023 Q1 |
| 2/22/2023 | 0.06SEK | - | 327.84 MSEK | - | 2022 Q4 |
| 11/25/2022 | -3.11SEK | - | 142.61 MSEK | - | 2022 Q3 |
| 8/18/2022 | -4.36SEK | - | 52.27 MSEK | - | 2022 Q2 |
| 2/24/2022 | -3.83SEK | - | 0.00SEK | - | 2021 Q4 |
EESG©
Eulerpool ESG Scorecard© for the Calliditas Therapeutics stock
EEnvironment
20
Environment
SSocial
20
Social
GGovernance (Corporate Governance)
4
Governance (Corporate Governance)
The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.
Calliditas Therapeutics shareholder structure
| % | Name |
|---|---|
99.03875% | |
0.81138% | |
0.43039% | |
0.17848% | |
0.12292% | |
0.08888% |
Calliditas Therapeutics Beneficial Ownership Filings (SEC 13D/G)
Calliditas Therapeutics Executives and Management Board
16 members · avg. age 59 · 44 % women
Ms. Renee Aguiar-Lucander (61)
Chief Executive Officer
13.05 M SEK
Management
Mr. Fredrik Johansson (46)
Chief Financial Officer
Mr. Andrew Udell (53)
President - North America
Mr. Frank Bringstrup (64)
Vice President - Regulatory Affairs
Mr. Brian Gorman
General Counsel
Mr. Jonathan Schur (70)
Group General Councel
Ms. Sandra Frithiof (48)
Head of Human Resources
Board of Directors
Mr. Elmar Schnee (64)
Independent Chairman of the Board
Ms. Molly Henderson (53)
Non-Executive Independent Director
Ms. Diane Parks (71)
Non-Executive Independent Director
Mrs. Hilde Furberg (65)
Non-Executive Independent Director
Mr. Henrik Stenqvist (56)
Non-Executive Independent Director
Dr. Elisabeth Bjork (62)
Non-Executive Independent Director
Calliditas Therapeutics Supply Chain
Calliditas Therapeutics Supply Chain
Correlation: how closely stock prices move together
| # | Name | Trend | |||
|---|---|---|---|---|---|
| 1 | 0.23 | 0.69 | — | ||
| 2 | 0.59 | — | — | ||
| 3 | -0.27 | -0.01 | — | ||
| 4 | Svenska Handelsbanken A | 0.17 | 0.08 | -0.25 | |
| 5 | 0 | 0.38 | -0.04 |
Frequently asked questions about Calliditas Therapeutics
The business model of Calliditas Therapeutics AB is focused on developing and commercializing novel treatments for rare kidney diseases. The company aims to address unmet medical needs by developing innovative therapies and providing improved outcomes for patients. Calliditas Therapeutics AB conducts extensive research and development to create effective and safe treatments, incorporating clinical trials to evaluate their efficacy. By partnering with healthcare professionals, institutions, and stakeholders, Calliditas Therapeutics AB seeks to maximize patient access to its products and contribute to the advancement of renal care.
Calliditas Therapeutics AB is primarily active in the pharmaceutical industry. With a focus on developing and commercializing innovative treatments, Calliditas Therapeutics AB specializes in rare and orphan diseases. As a specialized biopharmaceutical company, Calliditas Therapeutics AB is dedicated to improving the quality of life for patients suffering from severe diseases.
The main competitors of Calliditas Therapeutics AB in the market include pharmaceutical companies such as Mallinckrodt, Advicenne, and Retrophin.
Calliditas Therapeutics AB, a renowned biopharmaceutical company, has a rich history and background. Founded in 2004 and headquartered in Stockholm, Sweden, Calliditas focuses on developing novel treatments for rare kidney diseases. The company combines scientific expertise and innovative research to improve patients' lives. Calliditas Therapeutics AB went public in 2017 and trades on the Nasdaq Stockholm under the ticker symbol CALTX. With a strong commitment to patient care and leveraging cutting-edge technologies, Calliditas Therapeutics AB continues to make significant strides in the field of kidney disease therapies.
Calliditas Therapeutics AB has achieved several significant milestones. The company successfully completed a Phase 3 clinical trial for Nefecon, an investigational treatment for IgA nephropathy. In addition, Calliditas Therapeutics AB received Breakthrough Therapy designation from the U.S. FDA for Nefecon, recognizing its potential to address an unmet medical need. The company also entered into collaboration agreements with key partners, including Everest Medicines and Deva Holding, to further develop and commercialize its products. Furthermore, Calliditas Therapeutics AB successfully listed on the Nasdaq Stockholm exchange, improving visibility in the market. These achievements demonstrate the company's commitment to advancing innovative therapies and expanding its global presence.
Calliditas Therapeutics AB is primarily present in several countries and regions worldwide. The company has a strong presence in the United States, where it operates through its subsidiary, Calliditas Therapeutics Inc. Additionally, Calliditas Therapeutics AB is actively engaged in Europe, with significant operations and market presence in countries like Sweden, Germany, France, and the United Kingdom. The company strives to expand its reach and establish a global footprint by establishing partnerships and collaborations in different geographies. Calliditas Therapeutics AB focuses on developing innovative therapies and improving patient outcomes, benefiting individuals in various countries and regions through its dedicated efforts.
Calliditas Therapeutics AB represents a set of core values and a corporate philosophy that focus on innovation, commitment, and patient-centricity. The company is dedicated to developing and commercializing therapies for patients with rare diseases and other unmet medical needs. Calliditas Therapeutics AB believes in fostering a culture of excellence, collaboration, and integrity to deliver meaningful and transformative healthcare solutions. With a strong emphasis on research and development, the company aims to improve patients' quality of life and provide hope for those suffering from chronic diseases.
13 analysts currently rate the Calliditas Therapeutics stock: 10 recommend buying, 3 holding and 0 selling. For 2026, analysts expect Calliditas Therapeutics to generate revenue of 5.22 B SEK and earnings per share of 40.81 SEK.
The Calliditas Therapeutics share (CALTX.ST) is listed on 6 stock exchanges, including: Frankfurt (LC8.F), München (LC8.MU), Düsseldorf (LC8.DU), London (0A5R.L).
Calliditas Therapeutics AB is a Swedish biotechnology company focused on the development of medications for the treatment of rare diseases. The company was founded in 2004 and is headquartered in Stockholm. Calliditas is developing new therapeutic approaches for patients suffering from autoimmune and kidney diseases. The business model of Calliditas is based on the discovery, development, and commercialization of innovative medications that meet high medical needs and can have a significant impact on patients' lives. Calliditas conducts intensive research and development projects aimed at developing innovative drugs and treatment approaches that enable fast and effective healing. The main products of Calliditas are Nefecon, a medication for the treatment of IgA nephropathy, an inflammatory kidney disease, and Baylis Medical, which provides medical technology for diagnosing and treating kidney diseases. Nefecon is an innovative medication based on a unique proprietary technology platform that is designed to slow down the progression of IgA nephropathy. IgA nephropathy is a rare autoimmune disease that attacks the kidneys and can lead to irreversible damage. Calliditas also operates an extensive development program for a range of autoimmune diseases such as PBC, AAV, and Primary Sclerosing Cholangitis (PSC). Calliditas' research work aims to develop innovative drugs that target fast and effective treatment of these conditions. The company relies on a clinical pipeline that offers a wide range of potential therapy options. Calliditas has demonstrated a strong commitment to collaborating with leading academic institutions and the pharmaceutical industry to promote innovative research and utilize new technology platforms for drug development. The company strives to identify and build strategic partnerships. In summary, Calliditas is a leading biotechnology company developing innovative medications for the treatment of autoimmune and kidney diseases. The company has a clinical pipeline that offers a wide range of potential therapy options and is dedicated to research and development of innovative treatment approaches. Calliditas has built strong business partnerships with leading institutions and the pharmaceutical industry. The company aims to lead the healthcare industry in terms of research and innovation and improve the lives of patients worldwide.
The expected revenue of Calliditas Therapeutics is 5.22 B SEK. This figure is based on current financial data and reflects the company's business performance.
The expected profit of Calliditas Therapeutics is 2.19 B SEK. The net profit reflects the company's profitability after deducting all expenses.
The P/E ratio cannot be calculated for Calliditas Therapeutics at the moment.
The P/S cannot be calculated for Calliditas Therapeutics currently.
The Eulerpool Quality Score for Calliditas Therapeutics is 3/10.
The ISIN of Calliditas Therapeutics is SE0010441584. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.
The WKN of Calliditas Therapeutics is A2JP36. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.
The ticker of Calliditas Therapeutics is CALTX.ST. The ticker symbol is used to trade Calliditas Therapeutics shares on the stock exchange.
Calliditas Therapeutics is assigned to the 'Health' sector.
The dividends of Calliditas Therapeutics are distributed in SEK.
Calliditas Therapeutics stock
Calliditas Therapeutics Peer Group
Calliditas Therapeutics Ticker
Calliditas Therapeutics FIGI
All fundamentals and in-depth analysis of Calliditas Therapeutics
Our stock analysis for Calliditas Therapeutics stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Calliditas Therapeutics. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.